TCM
KALV

TCG Crossover Management’s KalVista Pharmaceuticals KALV Stock Holding History

TCG Crossover Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,163,356
Closed -$13.8M – 34
2024
Q1 		$13.8M Sell
1,163,356
-2,232,139
-66% -$29.8M 1.09% 26
2023
Q4 		$41.6M Hold
3,395,495
– – 4.61% 11
2023
Q3 		$32.7M Hold
3,395,495
– – 4.81% 7
2023
Q2 		$30.6M Hold
3,395,495
– – 5.01% 9
2023
Q1 		$26.7M Hold
3,395,495
– – 5.2% 7
2022
Q4 		$23M Buy
+3,395,495
New +$18.2M 4.05% 10

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return